摘要
目的探讨新辅助化疗对乳腺癌患者雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体-2(HER-2)和Ki67抗原标记指数表达的影响及意义。方法选取89例单侧女性乳腺癌患者,行氟尿嘧啶、表阿霉素和环磷酰胺(FEC化疗方案)新辅助化疗,采用免疫组化S-P法对化疗前后ER、PR、HER-2和Ki67的表达进行测定。观察其变化及与疗效间的关系。结果 NAC后完全缓解11例(12.4%);部分缓解51例(57.3%);病情稳定23例(25.8%);病情发展4例(4.5%)。行新辅助化疗后,ER阴性组、PR阴性组、Ki67阴性组的临床有效率显著升高,与阳性组比较差异均有统计学意义(P<0.05)。行新辅助化疗前后ER与Ki67的表达差异有统计学意义(P<0.05)。结论新辅助化疗前后ER、PR、HER-2和Ki67表达的变化可作为制定乳腺癌患者后期治疗方案、评估预后的指标。
Objective To probe the ER, PR, HER-2, Ki-67 expression and its significance of neoadjuvant chemotherapy for breast cancer patients. Methods 89 cases of female patients with unilateral breast cancer were selected, and treated by FEC neoadjuvant chemotherapy, then using immunohistochemis- try SP method to measure the ER, PR, HER-2 and Ki67 expression before and after chemotherapy. Correla- tion between the variation and efficacy were observed. Results After the NAC, there was complete remis- sion in 11 cases（ 12.4% ） ; partial remission in 51 cases（57. 3% ） ; stable disease in 23 cases（25. 8% ） ; progression of the disease in 4 cases（4. 5% ）. After the NAC, ER（-） group, PR（-） group, Ki67 （-）group clinical efficiency increased significantly compared with the positive group, there were significantly different （ P 〈 0. 05 ）. ER, Ki67 appear before and after the NAC statistically significant difference （ P 〈 0. 05 ）. Conclusions The expression change of ER, PR, HER-2 and Ki67 before and after neoadjuvant chemother- apy can be used as indicators to develop post-treatment programs and to assess the prognosis of the patients.
出处
《中国肿瘤临床与康复》
2013年第2期110-112,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
乳腺肿瘤
新辅助化疗
免疫组化
Breast neoplasms
Neoadjuvant chemotherapy
Immunohistochemistry
